A pilot study of the impact of genotype on nifedipine pharmacokinetics when used as a tocolytic

David Haas, Sara Quinney, Catherine L. McCormick, David R. Jones, Jamie Renbarger

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Objective.To characterize the pharmacokinetics of nifedipine when used for tocolysis in preterm labor and to determine the impact of genetics on these parameters. Study design.Pharmacokinetic study performed on women given tocolytic nifedipine. Over one dosing interval, drug concentrations, clinical data, and genotype for Cytochrome P450 (CYP)3A5 polymorphisms were obtained. Non-compartmental pharmacokinetic analysis was used to estimate nifedipine exposure at steady state. Results.The mean nifedipine area under the curve in 20 pregnant women was 86.1±61.1 ng/ml/h. The mean nifedipine exposure differed by expression of CYP3A5 (expressers [exp]: 139.5±97.3 ng/ml/h vs. nonexpressers[non]: 68.3 ± 31.8 ng/ml/h, p = 0.02). Four women consumed CYP3A inhibitors and this affected the nifedipine concentrations (p < 0.001). CYP3A5 expressers had less improvement in contraction frequency after the loading dose (p = 0.04), at steady state (p = 0.006), and at 0-1 h after the study dose (p < 0.001). Conclusions.CYP3A5 genotype plays a role in nifedipine concentration when used as a tocolytic.

Original languageEnglish
Pages (from-to)419-423
Number of pages5
JournalJournal of Maternal-Fetal and Neonatal Medicine
Volume25
Issue number4
DOIs
StatePublished - Apr 2012

Fingerprint

Tocolytic Agents
Nifedipine
Pharmacokinetics
Genotype
Cytochrome P-450 CYP3A
Tocolysis
Premature Obstetric Labor
Area Under Curve
Pregnant Women

Keywords

  • Nifedipine
  • pharmacogenetics
  • pharmacokinetics
  • preterm labor

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Obstetrics and Gynecology

Cite this

A pilot study of the impact of genotype on nifedipine pharmacokinetics when used as a tocolytic. / Haas, David; Quinney, Sara; McCormick, Catherine L.; Jones, David R.; Renbarger, Jamie.

In: Journal of Maternal-Fetal and Neonatal Medicine, Vol. 25, No. 4, 04.2012, p. 419-423.

Research output: Contribution to journalArticle

@article{79c5aa11c78c43c5b31c1b0ff74b9007,
title = "A pilot study of the impact of genotype on nifedipine pharmacokinetics when used as a tocolytic",
abstract = "Objective.To characterize the pharmacokinetics of nifedipine when used for tocolysis in preterm labor and to determine the impact of genetics on these parameters. Study design.Pharmacokinetic study performed on women given tocolytic nifedipine. Over one dosing interval, drug concentrations, clinical data, and genotype for Cytochrome P450 (CYP)3A5 polymorphisms were obtained. Non-compartmental pharmacokinetic analysis was used to estimate nifedipine exposure at steady state. Results.The mean nifedipine area under the curve in 20 pregnant women was 86.1±61.1 ng/ml/h. The mean nifedipine exposure differed by expression of CYP3A5 (expressers [exp]: 139.5±97.3 ng/ml/h vs. nonexpressers[non]: 68.3 ± 31.8 ng/ml/h, p = 0.02). Four women consumed CYP3A inhibitors and this affected the nifedipine concentrations (p < 0.001). CYP3A5 expressers had less improvement in contraction frequency after the loading dose (p = 0.04), at steady state (p = 0.006), and at 0-1 h after the study dose (p < 0.001). Conclusions.CYP3A5 genotype plays a role in nifedipine concentration when used as a tocolytic.",
keywords = "Nifedipine, pharmacogenetics, pharmacokinetics, preterm labor",
author = "David Haas and Sara Quinney and McCormick, {Catherine L.} and Jones, {David R.} and Jamie Renbarger",
year = "2012",
month = "4",
doi = "10.3109/14767058.2011.583700",
language = "English",
volume = "25",
pages = "419--423",
journal = "Journal of Maternal-Fetal and Neonatal Medicine",
issn = "1476-7058",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - A pilot study of the impact of genotype on nifedipine pharmacokinetics when used as a tocolytic

AU - Haas, David

AU - Quinney, Sara

AU - McCormick, Catherine L.

AU - Jones, David R.

AU - Renbarger, Jamie

PY - 2012/4

Y1 - 2012/4

N2 - Objective.To characterize the pharmacokinetics of nifedipine when used for tocolysis in preterm labor and to determine the impact of genetics on these parameters. Study design.Pharmacokinetic study performed on women given tocolytic nifedipine. Over one dosing interval, drug concentrations, clinical data, and genotype for Cytochrome P450 (CYP)3A5 polymorphisms were obtained. Non-compartmental pharmacokinetic analysis was used to estimate nifedipine exposure at steady state. Results.The mean nifedipine area under the curve in 20 pregnant women was 86.1±61.1 ng/ml/h. The mean nifedipine exposure differed by expression of CYP3A5 (expressers [exp]: 139.5±97.3 ng/ml/h vs. nonexpressers[non]: 68.3 ± 31.8 ng/ml/h, p = 0.02). Four women consumed CYP3A inhibitors and this affected the nifedipine concentrations (p < 0.001). CYP3A5 expressers had less improvement in contraction frequency after the loading dose (p = 0.04), at steady state (p = 0.006), and at 0-1 h after the study dose (p < 0.001). Conclusions.CYP3A5 genotype plays a role in nifedipine concentration when used as a tocolytic.

AB - Objective.To characterize the pharmacokinetics of nifedipine when used for tocolysis in preterm labor and to determine the impact of genetics on these parameters. Study design.Pharmacokinetic study performed on women given tocolytic nifedipine. Over one dosing interval, drug concentrations, clinical data, and genotype for Cytochrome P450 (CYP)3A5 polymorphisms were obtained. Non-compartmental pharmacokinetic analysis was used to estimate nifedipine exposure at steady state. Results.The mean nifedipine area under the curve in 20 pregnant women was 86.1±61.1 ng/ml/h. The mean nifedipine exposure differed by expression of CYP3A5 (expressers [exp]: 139.5±97.3 ng/ml/h vs. nonexpressers[non]: 68.3 ± 31.8 ng/ml/h, p = 0.02). Four women consumed CYP3A inhibitors and this affected the nifedipine concentrations (p < 0.001). CYP3A5 expressers had less improvement in contraction frequency after the loading dose (p = 0.04), at steady state (p = 0.006), and at 0-1 h after the study dose (p < 0.001). Conclusions.CYP3A5 genotype plays a role in nifedipine concentration when used as a tocolytic.

KW - Nifedipine

KW - pharmacogenetics

KW - pharmacokinetics

KW - preterm labor

UR - http://www.scopus.com/inward/record.url?scp=84863420236&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863420236&partnerID=8YFLogxK

U2 - 10.3109/14767058.2011.583700

DO - 10.3109/14767058.2011.583700

M3 - Article

C2 - 21644845

AN - SCOPUS:84863420236

VL - 25

SP - 419

EP - 423

JO - Journal of Maternal-Fetal and Neonatal Medicine

JF - Journal of Maternal-Fetal and Neonatal Medicine

SN - 1476-7058

IS - 4

ER -